335 related articles for article (PubMed ID: 33170084)
1. Cancer Stem Cell Markers in Relation to Patient Survival Outcomes: Lessons for Integrative Diagnostics and Next-Generation Anticancer Drug Development.
Dzobo K; Ganz C; Thomford NE; Senthebane DA
OMICS; 2021 Feb; 25(2):81-92. PubMed ID: 33170084
[TBL] [Abstract][Full Text] [Related]
2. Broadening Drug Design and Targets to Tumor Microenvironment? Cancer-Associated Fibroblast Marker Expression in Cancers and Relevance for Survival Outcomes.
Dzobo K; Dandara C
OMICS; 2020 Jun; 24(6):340-351. PubMed ID: 32496971
[TBL] [Abstract][Full Text] [Related]
3. Cancer Stem Cells-Origins and Biomarkers: Perspectives for Targeted Personalized Therapies.
Walcher L; Kistenmacher AK; Suo H; Kitte R; Dluczek S; Strauß A; Blaudszun AR; Yevsa T; Fricke S; Kossatz-Boehlert U
Front Immunol; 2020; 11():1280. PubMed ID: 32849491
[TBL] [Abstract][Full Text] [Related]
4. Cancer stem cells (CSCs) in cancer progression and therapy.
Najafi M; Farhood B; Mortezaee K
J Cell Physiol; 2019 Jun; 234(6):8381-8395. PubMed ID: 30417375
[TBL] [Abstract][Full Text] [Related]
5. Stem cell programs in cancer initiation, progression, and therapy resistance.
Huang T; Song X; Xu D; Tiek D; Goenka A; Wu B; Sastry N; Hu B; Cheng SY
Theranostics; 2020; 10(19):8721-8743. PubMed ID: 32754274
[TBL] [Abstract][Full Text] [Related]
6. Concise Review: Emerging Role of CD44 in Cancer Stem Cells: A Promising Biomarker and Therapeutic Target.
Yan Y; Zuo X; Wei D
Stem Cells Transl Med; 2015 Sep; 4(9):1033-43. PubMed ID: 26136504
[TBL] [Abstract][Full Text] [Related]
7. Expression of cancer stem cell markers in pancreatic intraepithelial neoplasias and pancreatic ductal adenocarcinomas.
Kure S; Matsuda Y; Hagio M; Ueda J; Naito Z; Ishiwata T
Int J Oncol; 2012 Oct; 41(4):1314-24. PubMed ID: 22824809
[TBL] [Abstract][Full Text] [Related]
8. Role of microRNAs in the regulation of breast cancer stem cells.
Liu S; Clouthier SG; Wicha MS
J Mammary Gland Biol Neoplasia; 2012 Mar; 17(1):15-21. PubMed ID: 22331423
[TBL] [Abstract][Full Text] [Related]
9. Characterization of cancer stem cells from different grades of human colorectal cancer.
Manhas J; Bhattacharya A; Agrawal SK; Gupta B; Das P; Deo SV; Pal S; Sen S
Tumour Biol; 2016 Oct; 37(10):14069-14081. PubMed ID: 27507615
[TBL] [Abstract][Full Text] [Related]
10. CD90 a potential cancer stem cell marker and a therapeutic target.
Shaikh MV; Kala M; Nivsarkar M
Cancer Biomark; 2016; 16(3):301-7. PubMed ID: 27062695
[TBL] [Abstract][Full Text] [Related]
11. Emerging functional markers for cancer stem cell-based therapies: Understanding signaling networks for targeting metastasis.
Marquardt S; Solanki M; Spitschak A; Vera J; Pützer BM
Semin Cancer Biol; 2018 Dec; 53():90-109. PubMed ID: 29966677
[TBL] [Abstract][Full Text] [Related]
12. Assessment of cancer stem cell marker expression in primary head and neck squamous cell carcinoma shows prognostic value for aldehyde dehydrogenase (ALDH1A1).
Szafarowski T; Sierdziński J; Ludwig N; Głuszko A; Filipowska A; Szczepański MJ
Eur J Pharmacol; 2020 Jan; 867():172837. PubMed ID: 31811857
[TBL] [Abstract][Full Text] [Related]
13. CD133+, CD166+CD44+, and CD24+CD44+ phenotypes fail to reliably identify cell populations with cancer stem cell functional features in established human colorectal cancer cell lines.
Muraro MG; Mele V; Däster S; Han J; Heberer M; Cesare Spagnoli G; Iezzi G
Stem Cells Transl Med; 2012 Aug; 1(8):592-603. PubMed ID: 23197865
[TBL] [Abstract][Full Text] [Related]
14. Pancreatic cancer stem cells: features and detection methods.
Ishiwata T; Matsuda Y; Yoshimura H; Sasaki N; Ishiwata S; Ishikawa N; Takubo K; Arai T; Aida J
Pathol Oncol Res; 2018 Oct; 24(4):797-805. PubMed ID: 29948612
[TBL] [Abstract][Full Text] [Related]
15. In vitro characterization of CD133
Nair RM; Balla MM; Khan I; Kalathur RKR; Kondaiah P; Vemuganti GK
BMC Cancer; 2017 Nov; 17(1):779. PubMed ID: 29162051
[TBL] [Abstract][Full Text] [Related]
16. Markers of pancreatic cancer stem cells and their clinical and therapeutic implications.
Gzil A; Zarębska I; Bursiewicz W; Antosik P; Grzanka D; Szylberg Ł
Mol Biol Rep; 2019 Dec; 46(6):6629-6645. PubMed ID: 31486978
[TBL] [Abstract][Full Text] [Related]
17. Aberrant expression of cancer stem cell markers (CD44, CD90, and CD133) contributes to disease progression and reduced survival in hepatoblastoma patients: 4-year survival data.
Bahnassy AA; Fawzy M; El-Wakil M; Zekri AR; Abdel-Sayed A; Sheta M
Transl Res; 2015 Mar; 165(3):396-406. PubMed ID: 25168019
[TBL] [Abstract][Full Text] [Related]
18. Analysis of multiple markers for cancer stem-like cells in human thyroid carcinoma cell lines.
Shimamura M; Nagayama Y; Matsuse M; Yamashita S; Mitsutake N
Endocr J; 2014; 61(5):481-90. PubMed ID: 24531915
[TBL] [Abstract][Full Text] [Related]
19. Resistance to Cell Death and Its Modulation in Cancer Stem Cells.
Safa AR
Crit Rev Oncog; 2016; 21(3-4):203-219. PubMed ID: 27915972
[TBL] [Abstract][Full Text] [Related]
20. CD44 and CD24 cannot act as cancer stem cell markers in human lung adenocarcinoma cell line A549.
Roudi R; Madjd Z; Ebrahimi M; Samani FS; Samadikuchaksaraei A
Cell Mol Biol Lett; 2014 Mar; 19(1):23-36. PubMed ID: 24363164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
